Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer

Curr Treat Options Oncol. 2024 Jan;25(1):66-83. doi: 10.1007/s11864-023-01162-4. Epub 2024 Jan 3.


Localized high-risk (HR) prostate cancer (PCa) is a heterogenous disease state with a wide range of presentations and outcomes. Historically, non-surgical management with radiotherapy and androgen deprivation therapy was the treatment option of choice. However, surgical resection with radical prostatectomy (RP) and pelvic lymph node dissection (PLND) is increasingly utilized as a primary treatment modality for patients with HRPCa. Recent studies have demonstrated that surgery is an equivalent treatment option in select patients with the potential to avoid the side effects from androgen deprivation therapy and radiotherapy combined. Advances in imaging techniques and biomarkers have also improved staging and patient selection for surgical resection. Advances in robotic surgical technology grant surgeons various techniques to perform RP, even in patients with HR disease, which can reduce the morbidity of the procedure without sacrificing oncologic outcomes. Clinical trials are not only being performed to assess the safety and oncologic outcomes of these surgical techniques, but to also evaluate the role of surgical resection as a part of a multimodal treatment plan. Further research is needed to determine the ideal role of surgery to potentially provide a more personalized and tailored treatment plan for patients with localized HR PCa.

Keywords: High-risk; Local therapy; Prostatectomy; Prostatic adenocarcinoma; Robotic; Surgery.

Publication types

  • Review

MeSH terms

  • Androgen Antagonists / therapeutic use
  • Androgens
  • Combined Modality Therapy
  • Humans
  • Lymph Node Excision / methods
  • Male
  • Prostatectomy / methods
  • Prostatic Neoplasms* / pathology
  • Prostatic Neoplasms* / surgery


  • Androgen Antagonists
  • Androgens